Etanercept biosimilar - Sunshine Guojian Pharmaceutical

Drug Profile

Etanercept biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: 301-S; Etacept; Etanar; Reumatocept®; Yisaipu

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Cipla; Sunshine Guojian Pharmaceutical
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2018 3SBio plans to file for manufacturing approval for a prefilled syringe dosage form of etanercept biosimilar in China, in the second half of 2018
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Launched for Plaque psoriasis in India (SC) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top